AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as ...

Cancer biotech Viracta Therapeutics has closed its doors, laying off all employees and winding down operations. The San Diego ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Omega Therapeutics has almost reached the end. With cash running low, the Novo Nordisk-partnered biotech has struck a deal ...

The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...